As of Nov 27
| -0.43 / -2.75%|
The 6 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 16.00, with a high estimate of 20.00 and a low estimate of 14.00. The median estimate represents a +5.19% increase from the last price of 15.21.
The current consensus among 6 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.